Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. CN112345750 - Molecular marker for predicting and monitoring disease course of new coronal pneumonia and application of molecular marker

Office
Chine
Numéro de la demande 202011213081.5
Date de la demande 03.11.2020
Numéro de publication 112345750
Date de publication 09.02.2021
Type de publication A
CIB
G01N 33/53
GPHYSIQUE
01MÉTROLOGIE; TESTS
NRECHERCHE OU ANALYSE DES MATÉRIAUX PAR DÉTERMINATION DE LEURS PROPRIÉTÉS CHIMIQUES OU PHYSIQUES
33Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes G01N1/-G01N31/146
48Matériau biologique, p.ex. sang, urine; Hémocytomètres
50Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
53Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
G01N 33/68
GPHYSIQUE
01MÉTROLOGIE; TESTS
NRECHERCHE OU ANALYSE DES MATÉRIAUX PAR DÉTERMINATION DE LEURS PROPRIÉTÉS CHIMIQUES OU PHYSIQUES
33Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes G01N1/-G01N31/146
48Matériau biologique, p.ex. sang, urine; Hémocytomètres
50Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
68faisant intervenir des protéines, peptides ou amino-acides
G01N 33/58
GPHYSIQUE
01MÉTROLOGIE; TESTS
NRECHERCHE OU ANALYSE DES MATÉRIAUX PAR DÉTERMINATION DE LEURS PROPRIÉTÉS CHIMIQUES OU PHYSIQUES
33Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes G01N1/-G01N31/146
48Matériau biologique, p.ex. sang, urine; Hémocytomètres
50Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
58faisant intervenir des substances marquées
CPC
G01N 33/5308
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
5308for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
G01N 33/6869
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
6869Interleukin
G01N 33/6893
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
68involving proteins, peptides or amino acids
6893related to diseases not provided for elsewhere
G01N 33/581
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
48Biological material, e.g. blood, urine
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
58involving labelled substances
581with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
G01N 2333/4737
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
46from vertebrates
47Assays involving proteins of known structure or function as defined in the subgroups
4701Details
4737C-reactive protein
G01N 2333/5412
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
2333Assays involving biological materials from specific organisms or of a specific nature
435from animals; from humans
52Assays involving cytokines
54Interleukins [IL]
5412IL-6
Déposants SHANGHAI PUBLIC HEALTH CLINICAL CENTER
上海市公共卫生临床中心
Inventeurs YU WENQIANG
于文强
XU PENG
徐鹏
YANG SHUAI
杨帅
RU DAOPING
茹道平
XU JIANQING
徐建青
Mandataires 上海领誉知识产权代理有限公司 31383
上海领誉知识产权代理有限公司 31383
Titre
(EN) Molecular marker for predicting and monitoring disease course of new coronal pneumonia and application of molecular marker
(ZH) 一种新冠肺炎病程预测和监控的分子标志物及其应用
Abrégé
(EN) The invention discloses a molecular marker for predicting and monitoring a new coronal pneumonia course, which is hyaluronic acid or a combination containing hyaluronic acid, and other markers in thecombination comprise interleukin, D-dimer and/or C reactive protein. The invention also relates to an application of the molecular marker as a molecular marker for predicting and monitoring a new coronal pneumonia course, and an application of a detection reagent of the molecular marker in preparation of a product for predicting and monitoring the new coronal pneumonia course. The invention findsthat the level of hyaluronic acid in the plasma of a patient with severe new coronal pneumonia is remarkably increased, the level of hyaluronic acid is closely related to changes of other molecules inthe patient with new coronal pneumonia, and it is found and verified for the first time that plasma hyaluronic acid can be used as a molecular marker for distinguishing mild symptoms and severe symptoms of the patient with new coronal pneumonia; the defect of lack of effective markers for predicting and monitoring the new coronal disease course in the prior art is overcome, and treatment of new coronal pneumonia patients is facilitated.
(ZH) 本发明公开了一种新冠肺炎病程预测和监控的分子标志物,其为透明质酸或含有透明质酸的组合,所述组合中的其他标志物包括白细胞介素、D‑二聚体和/或C反应蛋白。本发明还涉及上述分子标志物作为预测和监控新冠肺炎病程的分子标志物的应用,以及上述分子标志物的检测试剂在制备预测和监控新冠肺炎病程的产品中的应用。本发明发现重症新冠肺炎患者血浆中透明质酸水平显著升高,且透明质酸水平与新冠患者中其他分子变化密切相关,且首次发现并验证可将血浆透明质酸作为区分新冠患者轻症和重症的分子标志物,从而弥补了现有技术中缺失新冠病程预测和监控的有效标志物的不足,利于进行新冠肺炎患者的救治。
Documents de brevet associés